## ClinicalTrials.gov

# Transcranial Direct Current Stimulation Therapy for Sleepiness Related to Shift Work Disorder (tDCS SWORD)

**NCT Number: 03879044** 

Ulysses J. Magalang, MD
The Ohio State University
Professor of Medicine and Neuroscience
Division of Pulmonary, Critical Care, and Sleep Medicine
Director Sleep Disorders Center
241 West 11th Avenue, Suite 5000
Columbus, OH 43201
Office: 614-292- 4307/Clinic: 614-293-4925

**Study Title:** 

IRB Protocol Number: 2018H0139
IRB Approval date: 9July2018

Version: 21Mar2018

# The Ohio State University Consent to Participate in Research

**Transcranial Direct Current Stimulation Therapy for** 

Sleepiness Related to Shift Work Disorder (tDCS-SWORD)

This consent is NOT to be used for screening purposes.

Principal Investigators: Ulysses J. Magalang M.D.

- This is a consent form for research participation. It contains important information about this study and what to expect if you decide to participate. Please consider the information carefully. Feel free to discuss the study with your friends and family and to ask questions before making your decision whether or not to participate.
- Your participation is voluntary. You may refuse to participate in this study. If you decide to take part in the study, you may leave the study at any time. No matter what decision you make, there will be no penalty to you and you will not lose any of your usual benefits. Your decision will not affect your future relationship with The Ohio State University. If you are a student or employee at Ohio State, your decision will not affect your grades or employment status.
- You may or may not benefit as a result of participating in this study. Also, as explained below, your participation may result in unintended or harmful effects for you that may be minor or may be serious depending on the nature of the research.
- You will be provided with any new information that develops during the study that may affect your decision whether or not to continue to participate. If you decide to participate, you will be asked to sign this form and will receive a copy of the form. You are being asked to consider participating in this study for the reasons explained below.

# 1. Why is this study being done?

Transcranial direct current stimulation (tDCS) is a safe, noninvasive, and painless form of brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp. It has been used in various conditions including depression, anxiety, Parkinson's disease, and chronic pain.

The objective of this study is to determine if tDCS treatment in night-shift workers with shiftwork sleep disorder will improve sleepiness and alertness during the work hours.

The tDCS technique uses two electrodes, one placed on the head and one on another part of the body (such as the arm) to deliver a very small current through the electrode. A small percentage of the current is passed into the underlying brain tissue and the

Page 2 of 10 Form date: 01/May/12

Version: 21Mar2018

remainder is dispersed through skin and bone. By controlling the direction the current flows through the electrodes, we can increase the activity in your brain under the electrode.

# 2. How many people will take part in this study?

Up to 45 subjects with shift work sleep disorder will participate in this study:

## 3. What will happen if I take part in this study?

The research will include six (6) visits and last 2 weeks. The informed consent process may take place at a separate visit. You may already have participated in the screening visit. The screening visit is not included in the 6 visits for the study.

#### RESEARCH RELATED PROCEDURES:

After signing the consent you will have:

- **Medication List.** You will be asked about the medications that you regularly take including over-the-counter medications.
- Sitting **blood pressure** and pulse rate measurements.
- **Questionnaires** about your health history and well-being and symptoms related to sleep disorders.
- **Actigraphy.** This device is the size of a small wristwatch that measures activity and is a non-invasive method of monitoring human rest/activity cycle. The instructions for

the device use will be provided. The data is then downloaded into a computer.

- Cognitive Performance Testing. You will be asked to make judgements or decisions on stimuli such as words or images presented to you on a computer screen to track you your memory and thought process.
- Transcranial Direct Current Stimulation (tDCS). This battery-powered device will be used to deliver a mild direct electrical current passed between electrodes on the scalp as shown in Figure 1 for 30 min. Gel and medical bandages are used to secure the electrodes to the scalp. TDCS stimulation will be done prior

Figure 1. tDCS set-up.

Page 3 of 10 Form date: 01/May/12

CONSENT IRB Protocol Number: 2018H0139
Biomedical/Cancer IRB Approval date: 9July2018
Version: 21Mar2018

to the start of your shift work 3 times per week.

• Psychomotor vigilance task (PVT) testing. The PVT is a test that measures the speed with which subjects respond to a visual stimulus. It is a simple task where the subject presses a button as soon as the light appears. The light will turn on randomly every few seconds for 3 minutes. The purpose of the PVT is to measure sustained attention, and give a numerical measure of sleepiness by counting the number of lapses in attention of the tested subject. You will be provided with a min-IPAD and the PVT will be done prior to your shift work, and during your shift work (around 12 midnight and around 4 am). This will be repeated at the end of the first and second week.

- Karolinska Sleepiness Scale (KSS). You will be asked to rate how sleepy you are prior to your shift work, and during your shift work (around 12 midnight and around 4 am). This will be repeated at the end of the first and second week.
  - 9. Extremely sleepy, fighting sleep
  - 8. Sleepy, some effort to keep alert
  - 7. Sleepy, but no difficulty remaining awake
  - 6. Some signs of sleepiness
  - 5. Neither alert nor sleepy
  - 4. Rather alert
  - 3. Alert
  - 2. Very alert
  - 1. Extremely alert

## 4. How long will I be in the study?

The duration of the study is two weeks. Research visits will occur prior to your scheduled shift work. The duration of the individual research visits are as follows:

**A)** Visit 1 (stimulation #1)

During this visit, the following will be obtained for all subjects:

- a. Study Informed consent (if not already obtained)
- b. Resting blood pressure and pulse rate
- c. Changes to Medication

They will then receive active tDCS for 30 mins. PVT during the active tDCS

- d. Side effects questionnaire after the active tDCS
- e. Actigraphy equipment will be provided to be worn throughout the duration of the study. Instructions on how to wear an actigraph device around their wrist that measures both the rest-activity cycle will be provided.
- f. Expected visit length: 60 minutes
- **B)** Visit 2 (stimulation #2)

Version: 21Mar2018

During this visit, the following will be obtained for all subjects:

- a. Resting blood pressure and pulse rate
- b. Changes to Medication

They will then receive active tDCS for 30 mins. PVT during the active tDCS

- a. Side effects questionnaire after the active tDCS
- b. Expected visit length: 60 minutes
- **D)** Visit 3 (stimulation #3)

During this visit, the following will be obtained for all subjects:

- a. Resting blood pressure and pulse rate
- b. Changes to Medication

They will then receive active tDCS for 30 mins. PVT during the active tDCS.

- c. Side effects questionnaire after the active tDCS
- c. PVT and KSS (6 pm, 12MN, and 4 am)
- g. Expected visit length: 60 minutes

Visits 1-3 will occur during a one week period. Subjects will then be asked to obtain the KSS score and PVT during their shift work at 6 pm, 12 MN, and 4 am at the end of Visit 3.

E) Visits 4, 5, 6 represent the second week of tCDS active stimulation and will be similar to Visits 1-3 with an expected visit length of 60 minutes per visit and will occur over a one-week period.

Subjects will be asked to obtain the KSS score and PVT during their shift work at 6 pm, 12 MN, and 4 am at the end of Visit 6. In addition, at the end of Visit 6, the following will be obtained **after** the active tDCS

- i. Cognitive Tasks results
- ii. Epworth sleepiness scale (ESS)

Visit Schedule

Page 5 of 10 Form date: 01/May/12

IRB Protocol Number: 2018H0139 IRB Approval date: 9July2018 Version: 21Mar2018

Procedures	Visit #						
	S	1	2	3	4	5	6
Screening consent	X						
Study consent		X					
Medication list	X	X	X	X	X	X	X
Height and weight	X						
BP and Pulse rate	X	X	X	X	X	X	X
MNC	X						
HSAT, if applicable	X						
Pregnancy test, if applicable	X						
Cognitive tasks	X						X
ESS	X						X
Actigraphy		X	X	X	X	X	X
tDCS		X	X	X	X	X	X
Side-effects		X	X	X	X	X	X
*PVT		X		X			X
*KSS		X		X			X

<sup>\*</sup>obtained during the subjects' shift work at baseline and after every 3 tdcs stimulation session S= screening visit (requires a separate consent)

BP= blood pressure

MNC= modified neck circumference

HSAT= home sleep apnea test

tDCS= transcranial direct current stimulation

PVT= psychomotor vigilance test

KSS= Karolinska sleepiness scale

ESS= Epworth Sleepiness Scale

# 5. Can I stop being in the study?

You may leave the study at any time. If you decide to stop participating in the study, there will be no penalty to you, and you will not lose any benefits to which you are otherwise entitled. Your decision will not affect your future relationship with The Ohio State University.

# 6. What risks, side effects or discomforts can I expect from being in the study?

#### • Risks associated with tDCS:

The most common side effect of tDCS is a slight itching or tingling on the scalp. It is also possible to have scalp and skin irritation as a result of the electrodes. Most individuals report mild, transient tingling at the stimulation site resulting from tDCS. No studies thus far have provided evidence that tDCS produces more than a minimal risk. A recent review of studies involving tDCS in different conditions found that to date, the use of tDCS

Version: 21Mar2018

protocols in human trials has not produced any reports of a Serious Adverse Effect or irreversible injury across over 33,200 sessions and 1000 subjects with repeated sessions.

*Pain:* If you feel any pain during tDCS, inform the investigator or the research monitor or an alternate immediately. We will terminate the stimulation at once.

*Headache and Nausea*. Any report of significant or headache/nausea will result in the immediate termination of stimulation.

### • Risks associated with Actigraph:

There is no risk associated with this device as it is like wearing a wrist watch. You will be asked to take off the device when taking a shower or when swimming.

#### • Risks associated with Ouestionnaires:

You may become bored or uncomfortable completing the questionnaires.

#### • Risks associated with Blood Pressure Measurement:

You may feel uncomfortable when the blood pressure cuff inflates.

#### • Risks associated with PVT/cognitive performance tests:

There is no risk associated with this testing as you are merely pushing a button during the testing. However, you may become bored or uncomfortable during the testing.

## 7. What benefits can I expect from being in the study?

There are no expected direct benefits to you by participating in this study. In the future, you may benefit, if new strategies to manage patients with sleepiness emerge as a result of this research.

## 8. What other choices do I have if I do not take part in the study?

You may choose not to participate without penalty or loss of benefits to which you are otherwise entitled.

## 9. Will my study-related information be kept confidential?

Efforts will be made to keep your study-related information confidential. However, there may be circumstances where this information must be released. For example, personal information regarding your participation in this study may be disclosed if required by state law.

Also, your records may be reviewed by the following groups (as applicable to the research):

• Office for Human Research Protections or other federal, state, or international regulatory agencies;

Page 7 of 10 Form date: 01/May/12

Version: 21Mar2018

- U.S. Food and Drug Administration;
- The Ohio State University Institutional Review Board or Office of Responsible Research Practices;
- The sponsor supporting the study, their agents or study monitors; and
- Your insurance company (if charges are billed to insurance).

If this study is related to your medical care, your study-related information may be placed in your permanent hospital, clinic, or physician's office records. Authorized Ohio State University staff not involved in the study may be aware that you are participating in a research study and have access to your information.

You may also be asked to sign a separate Health Insurance Portability and Accountability Act (HIPAA) research authorization form if the study involves the use of your protected health information.

## 10. What are the costs of taking part in this study?

You will not be billed for any research procedure performed in the study. You and/or your insurance company will be billed for all costs associated with your **routine medical care** and normal physician visits.

## 11. Will I be paid for taking part in this study?

Participants who qualify for the study will receive up to \$500 compensation for participating in the study in the form of a check or by direct deposit (optional for OSU employees who may elect to receive payment by check). You will receive \$250 after Visit 3 and \$250 after Visit 6. In the event that you are unable to complete all the visits, compensation will be prorated for the visits that are completed. For check payments, it may take up to 6 weeks for participants to receive payment. All subject payments are taxable income.

# 12. What happens if I am injured because I took part in this study?

If you suffer an injury from participating in this study, you should notify the researcher or study doctor immediately, who will determine if you should obtain medical treatment at The Ohio State University Medical Center.

The cost for this treatment will be billed to you or your medical or hospital insurance. The Ohio State University has no funds set aside for the payment of health care expenses for this study.

# 13. What are my rights if I take part in this study?

Page 8 of 10 Form date: 01/May/12

IRB Protocol Number: 2018H0139
IRB Approval date: 9July2018
Version: 21Mar2018

If you choose to participate in the study, you may discontinue participation at any time without penalty or loss of benefits. By signing this form, you do not give up any personal legal rights you may have as a participant in this study.

You will be provided with any new information that develops during the course of the research that may affect your decision whether or not to continue participation in the study.

You may refuse to participate in this study without penalty or loss of benefits to which you are otherwise entitled.

An Institutional Review Board responsible for human subjects research at The Ohio State University reviewed this research project and found it to be acceptable, according to applicable state and federal regulations and University policies designed to protect the rights and welfare of participants in research.

## 14. Who can answer my questions about the study?

For questions, concerns, or complaints about the study you may contact **Dr. Ulysses Magalang. Tel: 614-293-4925.** 

For questions about your rights as a participant in this study or to discuss other study-related concerns or complaints with someone who is not part of the research team, you may contact Ms. Sandra Meadows in the Office of Responsible Research Practices at 1-800-678-6251.

If you are injured as a result of participating in this study or for questions about a study-related injury, you may contact **Dr. Ulysses Magalang. Tel: 614-293-4925.** 

Page 9 of 10 Form date: 01/May/12

CONSENT Biomedical/Cancer IRB Protocol Number: 2018H0139 IRB Approval date: 9July2018 Version: 21Mar2018

## Signing the consent form

I have read (or someone has read to me) this form and I am aware that I am being asked to participate in a research study. I have had the opportunity to ask questions and have had them answered to my satisfaction. I voluntarily agree to participate in this study.

I am not giving up any legal rights by signing this form. I will be given a copy of this form.

Printed name of subject	Signature of subject	Signature of subject					
		AM/PM					
	Date and time	12:/2/2 :/2					
Printed name of person authorized to consent (when applicable)	Signature of person authorized to consent for (when applicable)	subject					
		AM/PM					
Relationship to the subject	Date and time						
Investigator/Research Staff							
	ticipant or his/her representative before reques						
	s in this document. A copy of this form has be	_					
Printed name of person obtaining consent	Signature of person obtaining consent						
		AM/PM					
	Date and time	AlVI/I IVI					
Witness(es) - May be left blank if n	ot required by the IRB						
Printed name of witness	Signature of witness						
		AM/PM					
Printed name of witness	Date and time	AM/PM					
Printed name of witness	Date and time  Signature of witness	AM/PM					
Printed name of witness		AM/PM					

Page 10 of 10 Form date: 01/May/12